Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of MN-08 tablets in Alzheimer's disease
ChiCTR2200062073Phase 2Not yet recruiting
- Sponsor
- Beijing Tiantan Hospital
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of nitronaphthazine in Alzheimer's disease (AD) (8 arms), sponsored by Beijing Tiantan Hospital. Primary endpoints: Alzheimer's Disease Assessment Scale - Cognitive subscale (ADAS-Cog) and Severe Impairment Battery (SIB). Planned start Jul 2022; status: not yet recruiting.
02
Drugs
nitronaphthazine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on ChiCTR2200062073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200062073.